Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DYAI NASDAQ:ERYP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYAIDyadic International$0.77+2.9%$0.82$0.65▼$1.35$27.15M1.1851,265 shs340,605 shsERYPERYTECH Pharma$3.10$4.66$0.30▼$1.47$105.77M2.6993,510 shsN/AThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYAIDyadic International0.00%-5.04%-16.55%-12.53%-31.65%ERYPERYTECH Pharma0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYAIDyadic International$0.77+2.9%$0.82$0.65▼$1.35$27.15M1.1851,265 shs340,605 shsERYPERYTECH Pharma$3.10$4.66$0.30▼$1.47$105.77M2.6993,510 shsN/AThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYAIDyadic International0.00%-5.04%-16.55%-12.53%-31.65%ERYPERYTECH Pharma0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDYAIDyadic International 2.33Hold$3.00291.39% UpsideERYPERYTECH Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest DYAI and ERYP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2026DYAIDyadic International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDYAIDyadic International$3.09M9.04N/AN/A$0.03 per share25.55ERYPERYTECH Pharma$32.66M3.24N/AN/A$0.80 per share3.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDYAIDyadic International-$7.36M-$0.25N/AN/AN/A-239.67%-695.96%-78.24%5/13/2026 (Estimated)ERYPERYTECH Pharma-$240KN/AN/AN/AN/AN/AN/AN/AN/ALatest DYAI and ERYP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026DYAIDyadic International-$0.04N/AN/AN/A$0.90 millionN/A3/25/2026Q4 2025DYAIDyadic International-$0.03-$0.06-$0.03-$0.06$1.34 million$0.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDYAIDyadic InternationalN/AN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDYAIDyadic International4.082.682.68ERYPERYTECH Pharma0.323.653.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDYAIDyadic International27.95%ERYPERYTECH Pharma1.09%Insider OwnershipCompanyInsider OwnershipDYAIDyadic International29.50%ERYPERYTECH Pharma1.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDYAIDyadic International736.44 million25.69 millionOptionableERYPERYTECH Pharma4934.12 million33.46 millionNot OptionableDYAI and ERYP HeadlinesRecent News About These CompaniesPhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital MarketFebruary 21, 2024 | finanznachrichten.deRoyalty Pharma PLC Class A RPRXJanuary 19, 2024 | morningstar.comMErytech Pharma S.A.: Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXMJune 28, 2023 | finanznachrichten.dePhaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXMJune 28, 2023 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - June 26, 2023June 27, 2023 | finance.yahoo.comERYTECH and PHERECYDES announce merger and name change to PHAXIAM TherapeuticsJune 26, 2023 | finance.yahoo.comERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023June 23, 2023 | finance.yahoo.comErytech Pharma S.A.: ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuitJune 20, 2023 | finanznachrichten.deERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuitJune 20, 2023 | markets.buffalonews.comMTech, Pharma Stocks Lead European Equities Higher in Thursday TradingJune 15, 2023 | msn.comUpdate on Erytech merger with Pherecydes PharmaJune 15, 2023 | thepharmaletter.comTERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes PharmaJune 14, 2023 | finance.yahoo.comErytech's Battle With Activist Investor Echoes As Pherecydes Pharma Merger Vote Comes CloserJune 13, 2023 | benzinga.comMonthly information related to total number of voting rights and shares composing the share capital _May 31, 2023June 13, 2023 | finance.yahoo.comErytech Pharma S.A.: ERYTECH Responds to Akkadian's DisinformationJune 12, 2023 | finanznachrichten.deERYTECH Responds to Akkadian’s DisinformationJune 12, 2023 | finance.yahoo.comErytech Pharma S.A.: ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with PherecydesJune 5, 2023 | finanznachrichten.deERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with PherecydesJune 5, 2023 | finance.yahoo.comERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023May 24, 2023 | finance.yahoo.comPharma Stocks Lead European Equities Sharply Lower in Wednesday TradingMay 24, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDYAI and ERYP Company DescriptionsDyadic International NASDAQ:DYAI$0.77 +0.02 (+2.89%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$0.81 +0.05 (+6.20%) As of 05/8/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.ERYTECH Pharma NASDAQ:ERYPERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
